Works matching IS 02724391 AND DT 2023 AND VI 84 AND IP 2
Results: 16
Discovery of 4‐(4‐aminophenyl)‐6‐phenylisoxazolo[3,4‐b]pyridine‐3‐amine derivatives as novel FLT3 covalent inhibitors for the intervention of acute myeloid leukemia.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 296, doi. 10.1002/ddr.22032
- By:
- Publication type:
- Article
A novel copper chelator for the suppression of colorectal cancer.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 312, doi. 10.1002/ddr.22034
- By:
- Publication type:
- Article
Novel acetic acid derivatives containing quinazolin‐4(3H)‐one ring: Synthesis, in vitro, and in silico evaluation of potent aldose reductase inhibitors.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 275, doi. 10.1002/ddr.22031
- By:
- Publication type:
- Article
Two new alkaloids from Dendrobium nobile Lindl. exhibited neuroprotective activity, and dendrobine alleviated Aβ<sub>1−42</sub>‐induced apoptosis by inhibiting CDK5 activation in PC12 cells.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 262, doi. 10.1002/ddr.22030
- By:
- Publication type:
- Article
Pramipexole inhibits formalin‐induce acute and long‐lasting mechanical hypersensitivity via NF‐kB pathway in rats.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 253, doi. 10.1002/ddr.22029
- By:
- Publication type:
- Article
Thrombospondin‐1 mimic peptide PKHB1 induced endoplasmic reticulum stress‐mediated but CD47‐independent apoptosis in non‐small cell lung cancer.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 238, doi. 10.1002/ddr.22028
- By:
- Publication type:
- Article
PDE4 inhibitor Roflumilast modulates inflammation and lipid accumulation in PCOS mice to improve ovarian function and reduce DHEA‐induced granulosa cell apoptosis in vitro.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 226, doi. 10.1002/ddr.22027
- By:
- Publication type:
- Article
Progress of small molecules for targeted protein degradation: PROTACs and other technologies.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 337, doi. 10.1002/ddr.22026
- By:
- Publication type:
- Article
Treatment strategies and pharmacist‐led medication management for Helicobacter pylori infection.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 326, doi. 10.1002/ddr.22025
- By:
- Publication type:
- Article
Oridonin ameliorates acetaminophen‐induced acute liver injury through ATF4/PGC‐1α pathway.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 211, doi. 10.1002/ddr.22024
- By:
- Publication type:
- Article
Novel EGFR‐MAPK kinase and ABC transporter inhibitors for HepG2 resistant to Erlotinib.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 200, doi. 10.1002/ddr.22023
- By:
- Publication type:
- Article
A new series of thiazole‐hydrazone hybrids for Akt‐targeted therapy of non‐small cell lung cancer.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 185, doi. 10.1002/ddr.22022
- By:
- Publication type:
- Article
Urolithin A suppresses tumor progression and induces autophagy in gastric cancer via the PI3K/Akt/mTOR pathway.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 172, doi. 10.1002/ddr.22021
- By:
- Publication type:
- Article
Therapeutic role of Artemether in the prevention of hepatic steatosis through miR‐34a‐5p/PPARα pathway.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 156, doi. 10.1002/ddr.22020
- By:
- Publication type:
- Article
Anlotinib improves bile duct ligature‐induced liver fibrosis in rats via antiangiogenesis regulated by VEGFR2/mTOR pathway.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 143, doi. 10.1002/ddr.22019
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Drug Development Research, 2023, v. 84, n. 2, p. 141, doi. 10.1002/ddr.21944
- Publication type:
- Article